(Q34674787)

3 August 2017

1 reference

title

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. (English)

1 reference

3 August 2017

main subject

peginterferon alfa-2a

1 reference

1

K Rajender Reddy

1 reference

3 August 2017

Marlene W Modi

2

1 reference

3 August 2017

Simon Pedder

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Advanced Drug Delivery Reviews

3 August 2017

published in

1 reference

3 August 2017

volume

54

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

571-586

1 reference

Pegylation: a novel process for modifying pharmacokinetics

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Clinical Pharmacokinetics of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

A branched monomethoxypoly(ethylene glycol) for protein modification

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Early predictors of response to treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

A pharmacokinetic model for alpha interferon administered subcutaneously

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900028-5

7 January 2021

10.1016/S0169-409X(02)00028-5

Identifiers

DOI

1 reference

release_f3l6okxp25ee5nl62aydgcbkkq

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f3l6okxp25ee5nl62aydgcbkkq

24 November 2022

mapped directly with Wikidata item

1 reference